Mapping of the antigenic regions of streptokinase in humans after streptokinase therapy.

Streptokinase (SK) is efficaciously used as a thrombolytic drug for the treatment of myocardial infarction. Being a bacterial protein, SK is immunogenic in humans. Therefore, resulting from SK therapy, patients become immunized and anti-SK antibody (Ab) titers rise post-treatment. High Ab titers might provoke severe immune reactions during SK therapy and neutralize SK activity, preventing effective thrombolysis. Spot synthesis combined with peptide library techniques is a useful tool for studying protein-peptide interactions on continuous cellulose membranes. Here, we report on the mapping of antigenic regions of SK using a spot-synthesized peptide library and human total sera from patients receiving SK therapy. All tested samples have high anti-SK Ab titers and most of them show significant SK neutralizing capacity. Individual variations in peptide recognition were detected. However, patients treated with SK tend, in general, to show a common regional binding pattern, including residues 1-20, 130-149, 170-189, and 390-399. This is the first study reporting the probing of a cellulose-bound set of peptides with total human sera.

[1]  J. Tang,et al.  Crystal structure of the catalytic domain of human plasmin complexed with streptokinase. , 1998, Science.

[2]  G. Sahni,et al.  Role of the amino‐terminal region of streptokinase in the generation of a fully functional plasminogen activator complex probed with synthetic peptides , 1998, Protein science : a publication of the Protein Society.

[3]  H. White,et al.  Mapping the antigenic regions of streptokinase in humans before and after streptokinase therapy. , 1995, Molecular immunology.

[4]  R. Frank,et al.  Spot synthesis of overlapping peptides on paper membrane supports enables the identification of linear monoclonal antibody binding determinants on morbillivirus phosphoproteins. , 1995, Veterinary microbiology.

[5]  P. Henklein,et al.  Interaction between a Fab fragment against gp41 of human immunodeficiency virus 1 and its peptide epitope: characterization using a peptide epitope library and molecular modeling. , 1995, Protein engineering.

[6]  A. Kramer,et al.  Combinatorial Cellulose-Bound Peptide Libraries: Screening Tools for the Identification of Peptides That Bind Ligands with Predefined Specificity , 1994 .

[7]  W. Littler,et al.  The significance of anti‐streptokinase antibodies , 1994, Clinical and experimental immunology.

[8]  G. Morris,et al.  Streptokinase neutralisation titres up to 866 days after intravenous streptokinase for acute myocardial infarction. , 1993, British heart journal.

[9]  G. Reed,et al.  A functional analysis of the antigenicity of streptokinase using monoclonal antibody mapping and recombinant streptokinase fragments. , 1993, Journal of immunology.

[10]  H. White,et al.  Neutralizing antibodies to streptokinase four years after intravenous thrombolytic therapy. , 1993, The American journal of cardiology.

[11]  W. Antuch,et al.  High Level Expression of Streptokinase in Escherichia Coli , 1992, Bio/Technology.

[12]  Ø. Bruserud,et al.  At least five antigenic epitopes on the streptokinase molecule are recognized by human CD4+ TCRαβ+ T cells , 1992 .

[13]  David Hunt,et al.  ISIS-3 - A RANDOMIZED COMPARISON OF STREPTOKINASE VS TISSUE PLASMINOGEN-ACTIVATOR VS ANISTREPLASE AND OF ASPIRIN PLUS HEPARIN VS ASPIRIN ALONE AMONG 41,299 CASES OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION , 1992 .

[14]  R. Stockley,et al.  Immunoglobulin response to intravenous streptokinase in acute myocardial infarction. , 1991, British heart journal.

[15]  D. Rosenstreich,et al.  Use of streptokinase as a recall antigen for lymphocyte proliferation testing in vitro. , 1991, The Journal of allergy and clinical immunology.

[16]  H. Malke,et al.  Streptokinase mutations relieving Escherichia coli K-12 (prlA4) of detriments caused by the wild-type skc gene , 1989, Journal of bacteriology.

[17]  L. Wannamaker,et al.  PHYSICAL AND IMMUNOLOGICAL DIFFERENCES AMONG STREPTOKINASES , 1965, The Journal of experimental medicine.

[18]  L. Weinstein.  Antigenic Dissimilarity of Streptokinases , 1953, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[19]  S. Cross,et al.  Raised levels of antistreptokinase antibody and neutralization titres from 4 days to 54 months after administration of streptokinase or anistreplase. , 1993, European heart journal.

[20]  R. Frank.  Spot-synthesis: an easy technique for the positionally addressable, parallel chemical synthesis on a membrane support , 1992 .

[21]  P. Stern.  Predicting antigenic sites on proteins. , 1991, Trends in biotechnology.

[22]  B. Roe,et al.  Nucleotide sequence of the streptokinase gene from Streptococcus equisimilis H46A. , 1985, Gene.

[23]  E. Veys,et al.  Letter: HL-A and infective sacroileitis. , 1974, Lancet.

[24]  W. Tillett,et al.  FIBRINOLYTIC ACTIVITY OF HEMOLYTIC STREPTOCOCCI. THE DEVELOPMENT OF RESISTANCE TO FIBRINOLYSIS FOLLOWING ACUTE HEMOLYTIC STREPTOCOCCUS INFECTIONS. , 1934, The Journal of clinical investigation.